Dorina van der Mey

Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: A randomized controlled trial

Henrik Watz, Johannes Nagelschmitz, Anne Kirsten et al. · Pulmonary Pharmacology & Therapeutics · 2019 · 65 citations

Non-cystic Fibrosis Bronchiectasis, Advanced Lung Disease, Pathology +6

IMI – oral biopharmaceutics tools project – evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds

Alison Margolskee, Adam S. Darwich, Xavier Pépin et al. · European Journal of Pharmaceutical Sciences · 2016 · 42 citations · Full text

Pharmacokinetic Modeling, Biochemistry, Medicine +8

First‐in‐man–proof of concept study with molidustat: a novel selective oral HIF‐prolyl hydroxylase inhibitor for the treatment of renal anaemia

M. Böttcher, Silvia Lentini, Erich R. Arens et al. · British Journal of Clinical Pharmacology · 2018 · 37 citations · Full text

Can dosage form-dependent food effects be predicted using biorelevant dissolution tests? Case example extended release nifedipine

Cord J. Andreas, Irena Tomaszewska, Uwe Muenster et al. · European Journal of Pharmaceutics and Biopharmaceutics · 2016 · 36 citations

Nutrition, Biorelevant Dissolution Tests, Dietary Exposure +9

Dualsteric Muscarinic Antagonists–Orthosteric Binding Pose Controls Allosteric Subtype Selectivity

Jens Schmitz, Dorina van der Mey, Marcel Bermúdez et al. · Journal of Medicinal Chemistry · 2014 · 34 citations · Full text

Pharmacotherapy, Chemical Biology, Molecular Pharmacology +16